Aurora and MedReleaf Australia Launch IndiMed Tempo 26, Further Strengthening Product Offerings for Medical Cannabis Patients
Tempo 26 will add to the portfolio of products available, giving doctors the ability to prescribe from a wider range of options for medical cannabis patients.
- Tempo 26 will add to the portfolio of products available, giving doctors the ability to prescribe from a wider range of options for medical cannabis patients.
- "We are proud to further expand the variety of high-quality medical cannabis products that Australian patients can access through the MedReleaf Concession Scheme, and with the addition of Tempo 26, doctors and patients now have more control and choice about their medical cannabis treatment than ever before," says Miguel Martin, CEO of Aurora Cannabis.
- "We are strongly committed to our patient-first approach to cannabis and ensuring access to medical patients, in Australia, and around the world."
- The MCS was developed by MedReleaf Australia and Aurora to provide high-quality products and enhance patient access to medical cannabis, which is not covered by the Pharmaceutical Benefits Scheme (PBS).